Abbott Laboratories Pharmaceutical Products Division; Withdrawal of Approval of New Drug Applications for CYLERT (Pemoline) Tablets, 18.75 Milligrams, 37.5 Milligrams, and 75 Milligrams, and CYLERT (Pemoline) Chewable Tablets, 37.5 Milligrams
1 recorded connections shown. Select a record, office or person to follow its source references.
Start with
and connect to
Browse all held record sources
Zoom to read. Drag to explore. Select a connection.
Abbott Laboratories Pharmaceutical Products Division; Withdrawal of Approval of New Drug Applications for CYLERT (Pemoline) Tablets, 18.75 Milligrams, 37.5 Milligrams, and 75 Milligrams, and CYLERT (Pemoline) Chewable Tablets, 37.5 Milligrams
Federal rule or notice · As of May 23, 2023
The source record
As of May 23, 2023; may be out of date.
- Document number
- 2023-10924
- Document type
- Notice
- Title
- Abbott Laboratories Pharmaceutical Products Division; Withdrawal of Approval of New Drug Applications for CYLERT (Pemoline) Tablets, 18.75 Milligrams, 37.5 Milligrams, and 75 Milligrams, and CYLERT (Pemoline) Chewable Tablets, 37.5 Milligrams
- Publication date
- 2023-05-23
- Action
- Notice.
- Html url
- https://www.federalregister.gov/d/2023-10924
- Created at
- 2026-09-24T17:40:29.110072
- Updated at
- 2026-09-24T17:40:29.110072
Every link on this map
The same connections as a table, with the reason each one is here.
| Federal rule or notice | What this connects to | Abbott Laboratories Pharmaceutical Products Division; Withdrawal of Approval of New Drug Applications for CYLERT (Pemoline) Tablets, 18.75 Milligrams, 37.5 Milligrams, and 75 Milligrams, and CYLERT (Pemoline) Chewable Tablets, 37.5 Milligrams has a recorded connection to Federal rule or notice. | None |